How do I treat patients who have relapsed after quadruplet regimen in the first-line in MM?

The Multiple Myeloma Hub was pleased to speak to Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked, How do I treat patients who have relapsed after quadruplet regimen in the first-line in multiple myeloma (MM)?
Dr Paul Richardson shares his approach to treating patients with newly diagnosed MM who become refractory to daratumumab and other quadruplet regimens in the first-line. He discusses second-line treatment strategies following the failure of quadruplet therapies, including the emergence of novel treatment options such as CAR T-cell therapies, bispecific antibodies, and other immunotherapies in earlier lines. Dr Richardson also emphasizes the importance of personalizing treatments based on patient factors, such as age, fitness, and treatment history, highlighting both established and emerging therapies for relapsed MM.